Publication
A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901).
Toshifumi Yamaguchi, Ryohei Kawabata, Yusuke Akamaru, Hidekazu Hirano, Keijiro Sugimura, Yasuhiro Miyazaki, Yoshihiro Kakeji, Yosuke Kito, Takashi Nomura, Takeshi Kawakami, Masahiro Tanemura, Atsushi Takeno, Hiroyuki Okuda, Tomohiro Matsushima, Toshio Shimokawa, Yukinori Kurokawa, Shunji Endo, Narikazu Boku, Taroh Satoh
- Source
- PubMed
- Retrieved
- Sep 19, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260919-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Gastric Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available